Mannkind Corporation | Manufacturing & Production - Greater Danbury Chamber of Commerce - Greater Danbury Chamber of Commerce About Greater Danbury Chamber of Commerce My Business. All rights reserved. At MannKind our employees are our number one asset, and we continue becoming a tight-knit community where each of us plays a critical role in our collective success. MannKind was established in 1991, and is headquartered in Westlake Village, Calif., with a manufacturing and R&D facility based in Danbury, Conn. At MannKind, we are committed to developing and commercializing innovative therapeutic products and devices for people living with endocrine and orphan lung diseases. Full Prescribing Information, including BOXED WARNING, Instructions for Use, and Medication Guide can be accessed at afrezza.com. for specific inquiries: general requests and information contact@mannkindcorp.com 818.661.5000 investor relations Box 43006 Providence RI 02940-3006 Courier Delivery: 150 Royall St., Suite 101 Canton, MA 02021 View all Recent Releases $84K-$119K Per Year (Glassdoor est.) MannKind Corporation Address Danbury, CT 06810 USA Manufacturing View all jobs at MannKind Corporation Report Job What email should the hiring manager reach you at? 2023 MannKind Corporation. MannKind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, Connecticut. Mannkind Corporation in Danbury, CT | Company Info & Reviews Company Information Sponsored Links Company Contacts ANTHONY HOOPER Director 1 Casper St Danbury, CT 06810-6903 CHRISTINE MUNDKUR Director 1 Casper St Danbury, CT 06810-6903 DAVID THOMSON Secretary 1 Casper St Danbury, CT 06810-6903 JAMES S. SHANNON Director 1 Casper St About this job. Corporate Governance. More. Upload your resume. Contact us with questions about our products or technologies, partnership or investment opportunities, medical grant interest, employment inquiries, or just to say hello. Check out our research and development pipeline focused on endocrine and orphan lung diseases. Mannkind Corporation Manufacturing & Production One Casper Street Building 8 Danbury CT 06810 (203) 796-3410 (203) 798-7740 1 Casper St. Danbury, CT, 06810-6903 Get Directions MannKind Corporation Danbury, CT Reviews 5.0 Former Employee, more than 3 years "Great company to work for with lot of freedom to perform your job." Jan 6, 2014 - Senior Scientist in Danbury, CT Recommends Neutral Outlook Approves of CEO Pros Revised 10/2018 Associate Director, Regulatory Affairs. 3.8 out of 5 stars. Senior Associate Manager, Quality Engineer. My Chamber. Danbury, CT Easy Apply 16d. Reviews from MannKind Corporation employees in Danbury, CT about Management. Position Summary: MannKind Corporation currently has an open position for an experienced Microbiologist to join our Inhalation Research Team in Danbury, CT. Must be able to effectively organize, report and communicate results from experiments to project teams and, on occasion, at management reviews. Write a review. Website: www.mannkindcorp.com Website. Director, Pharmaceutical Research. MannKind Corporation. Corporate Governance. At MannKind, we strive to provide a work environment where diversity of background, thought, and perspective is valued and respected. Find salaries. Danbury, CT Easy Apply 30d+. (203) 207-0912. Chris Bosak / Hearst Connecticut Media Show More Show Less 6 of 6 Easily apply. Find jobs. Est. Claim this business. Find company research, competitor information, contact details & financial data for Mannkind Corporation of Danbury, CT. Get the latest business insights from Dun & Bradstreet. Ms.","language":"en","releaseDate":{"dateUTC":"2020-03-24T13:00:00","date":"2020-03-24T09:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Jennifer Grancio Appointed to MannKind Board of Directors","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16856/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":{"url":"http://investors.mannkindcorp.com/static-files/0817c9bd-b333-4719-800d-6a1440a04a20","altText":"Jennifer Grancio"},"createdOnUTC":"2020-03-24T13:01:23","lastUpdatedUTC":"2020-04-14T23:34:29"},{"id":16851,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16851","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-refocuses-pipeline-resources-response-covid-19-pandemic"},"title":"MannKind Refocuses Pipeline Resources in Response to COVID-19 Pandemic","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , March 17, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products, today announced that it is adjusting research and development resources that were reserved for its","language":"en","releaseDate":{"dateUTC":"2020-03-17T13:00:00","date":"2020-03-17T09:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Refocuses Pipeline Resources in Response to COVID-19 Pandemic","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16851/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":{"url":"http://investors.mannkindcorp.com/static-files/d825bb91-3610-4420-86f7-1bdc005666f2","altText":"MannKind Refocuses Pipeline Resources in Response to COVID-19 Pandemic"},"createdOnUTC":"2020-03-17T13:02:11","lastUpdatedUTC":"2020-04-14T23:35:21"},{"id":16901,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16901","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-reports-2019-fourth-quarter-and-full-year"},"title":"MannKind Corporation Reports 2019 Fourth Quarter and Full Year Financial Results","type":{"title":"Earnings","id":3896},"teaser":"Conference Call to Begin Today at 9:00 AM ET 2019 Total Revenue of $63.0 million 2019 Afrezza Net Revenue of $25.3 million ; +46% vs. 2018 2019 Collaborations and Services Revenue of $37.7 million ; +257% vs. 2018 4Q 2019 Total Revenue of $16.0 million 4Q 2019 Afrezza Net Revenue of $7.8","language":"en","releaseDate":{"dateUTC":"2020-02-25T13:00:00","date":"2020-02-25T08:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Reports 2019 Fourth Quarter and Full Year Financial Results","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16901/html"}}],"additionalFormats":[],"categories":[],"unpublishOn":null,"thumbnail":{"url":"http://investors.mannkindcorp.com/static-files/d581f91b-2b3f-4113-b208-c7f69f9bc256","altText":"MannKind Corporation Reports 2019 Fourth Quarter and Full Year Financial Results"},"createdOnUTC":"2020-04-13T16:19:54","lastUpdatedUTC":"2020-04-14T23:36:02"},{"id":16936,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16936","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-present-9th-annual-svb-leerink-global"},"title":"MannKind Corporation to Present at the 9th Annual SVB Leerink Global Healthcare Conference","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Feb. 24, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, announced today that it will","language":"en","releaseDate":{"dateUTC":"2020-02-24T23:25:00","date":"2020-02-24T18:25:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Present at the 9th Annual SVB Leerink Global Healthcare Conference","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16936/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":{"url":"http://investors.mannkindcorp.com/static-files/30defea8-4803-438a-af7a-2f39bd68ca1a","altText":"leerink"},"createdOnUTC":"2020-04-16T15:56:57","lastUpdatedUTC":"2020-04-16T15:59:27"},{"id":16941,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16941","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-presents-novel-scientific-data-13th-international"},"title":"MannKind Presents Novel Scientific Data at 13th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2020)","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Feb. 20, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) today announced the presentation of results from multiple clinical studies of Afrezza (insulin human) Inhalation Powder and MannKinds BluHale technology system. Committed to diversity, at MannKind we depend on a rich blend of . Marlborough, MA 01752, Terms of Use Address: 1 Casper St Danbury, CT, 06810-6903 United States See other locations Phone: ? View job. Committed to diversity, at MannKind we depend on a rich blend of ideas, backgrounds, and working styles in our quest to change the world for the better. All rights reserved. Get MannKind Corporation can be contacted at (203) 798-8000. ","language":"en","releaseDate":{"dateUTC":"2020-11-30T13:00:00","date":"2020-11-30T08:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Sabrina Kay Appointed to MannKind Board of Directors","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17261/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-11-30T13:02:46","lastUpdatedUTC":"2020-11-30T13:02:46"},{"id":17256,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17256","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-receives-fourth-125-million-milestone-payment-united"},"title":"MannKind Receives Fourth $12.5 Million Milestone Payment from United Therapeutics","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Nov. 19, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today announced that it has achieved the final development milestone under its licensing and collaboration agreement with United Therapeutics for the development and commercialization of a dry powder","language":"en","releaseDate":{"dateUTC":"2020-11-19T22:00:00","date":"2020-11-19T17:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Receives Fourth $12.5 Million Milestone Payment from United Therapeutics","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17256/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-11-19T22:01:18","lastUpdatedUTC":"2020-11-19T22:01:18"},{"id":17241,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17241","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-reports-2020-third-quarter-financial"},"title":"MannKind Corporation Reports 2020 Third Quarter Financial Results","type":{"title":"Earnings","id":3896},"teaser":"Conference Call to Begin Today at 5:00 PM ET 3Q 2020 U.S. Afrezza Net Revenue of $7.3 million ; +27% vs. 3Q 2019 3Q YTD 2020 U.S. Afrezza Net Revenue of $22.1 million ; +31% vs. 3Q YTD 2019 Cash and cash equivalents of $52.4 million at September 30, 2020 On track to complete Treprostin i l","language":"en","releaseDate":{"dateUTC":"2020-11-04T21:00:00","date":"2020-11-04T16:00:00","timezone":{"name":"America/New_York","code":"EST"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Reports 2020 Third Quarter Financial Results","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17241/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-11-04T21:00:54","lastUpdatedUTC":"2020-11-04T21:00:54"},{"id":17221,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17221","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-hold-2020-third-quarter-financial-results"},"title":"MannKind Corporation to Hold 2020 Third Quarter Financial Results Conference Call on November 4, 2020","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Oct. 29, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) will release its 2020 third quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on Wednesday,","language":"en","releaseDate":{"dateUTC":"2020-10-29T12:00:00","date":"2020-10-29T08:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Hold 2020 Third Quarter Financial Results Conference Call on November 4, 2020","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17221/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-10-29T12:03:08","lastUpdatedUTC":"2020-10-29T12:03:08"},{"id":17216,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17216","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-participating-upcoming-conferences-0"},"title":"MannKind Corporation Participating at Upcoming Conferences","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Sept. 08, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with diabetes and orphan lung diseases, announced today that it will be participating at","language":"en","releaseDate":{"dateUTC":"2020-09-08T12:00:00","date":"2020-09-08T08:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Participating at Upcoming Conferences","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17216/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-09-08T12:02:05","lastUpdatedUTC":"2020-09-08T12:02:05"},{"id":17166,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17166","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/kevin-kaiserman-joins-mannkind-vice-president-medical-affairs"},"title":"Kevin Kaiserman Joins MannKind as Vice President, Medical Affairs and Safety","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Aug. 31, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) today announced that Kevin Kaiserman , MD, has joined the company as Vice President, Medical Affairs and Safety and will assume full responsibility for leading MannKinds medical affairs, field medical","language":"en","releaseDate":{"dateUTC":"2020-08-31T13:00:00","date":"2020-08-31T09:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Kevin Kaiserman Joins MannKind as Vice President, Medical Affairs and Safety","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17166/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":{"url":"http://investors.mannkindcorp.com/static-files/909d0eaa-1358-4f4a-9ec0-b8312b87ba4e","altText":"Kevin Kaiserman "},"createdOnUTC":"2020-08-31T13:01:25","lastUpdatedUTC":"2020-08-31T13:13:16"},{"id":17131,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17131","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-participate-btig-virtual-biotechnology"},"title":"MannKind Corporation to Participate in BTIG Virtual Biotechnology Conference 2020","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , Aug. 07, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) , a company focused on the development and commercialization of inhaled therapeutic products for patients with diabetes and orphan lung diseases, announced today that its Chief Executive Officer,","language":"en","releaseDate":{"dateUTC":"2020-08-07T21:00:00","date":"2020-08-07T17:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Participate in BTIG Virtual Biotechnology Conference 2020","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17131/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-08-07T21:00:41","lastUpdatedUTC":"2020-08-07T21:00:41"},{"id":17116,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17116","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-reports-2020-second-quarter-financial"},"title":"MannKind Corporation Reports 2020 Second Quarter Financial Results","type":{"title":"Earnings","id":3896},"teaser":"Conference Call to Begin Today at 5:00 PM ET 2Q 2020 Afrezza Net Revenue of $7.0 million ; +15% vs. 2Q 2019 1H 2020 Afrezza Net Revenue of $15.0 million ; +35% vs. 1H 2019 Cash and cash equivalents of $63.2 million at June 30, 2020 Non-GAAP cash used in operating activities decreased by 37% vs.","language":"en","releaseDate":{"dateUTC":"2020-08-05T20:00:00","date":"2020-08-05T16:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Reports 2020 Second Quarter Financial Results","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17116/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-08-05T20:00:48","lastUpdatedUTC":"2020-08-05T20:00:48"},{"id":17091,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17091","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-hold-2020-second-quarter-financial-results"},"title":"MannKind Corporation to Hold 2020 Second Quarter Financial Results Conference Call on August 5, 2020","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , July 29, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) will release its 2020 second quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on Wednesday, August","language":"en","releaseDate":{"dateUTC":"2020-07-29T21:00:00","date":"2020-07-29T17:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Hold 2020 Second Quarter Financial Results Conference Call on August 5, 2020","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17091/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-07-29T21:00:49","lastUpdatedUTC":"2020-07-29T21:00:49"},{"id":17086,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17086","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/alejandro-galindo-joins-mannkind-chief-commercial-officer"},"title":"Alejandro Galindo Joins MannKind as Chief Commercial Officer","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , July 20, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ: MNKD) today announced that effective August 4, 2020 , Alejandro Galindo , M.B.A, M.S., will be leading MannKinds commercial operations as Chief Commercial Officer. Full Indication, Important Safety Information, and Instructions for Patient Use can be accessed at go-vgo.com. All Jobs Start of main content. 1 Casper Street Danbury, CT 06810 203.798.8000 30930 Russell Ranch Road, Suite 300 Westlake Village, CA 91362 818.661.5000 Who is your transfer agent? Full-Time At MannKind our employees are our number one asset, and we continue becoming a tight-knit community where each of us plays a critical role in our collective success. Our approach begins with our cutting-edge technology and is driven by solutions-based scientists and medical professionals who are dedicated to helping people experience the very best life has to offer. The primary responsibility will be to plan, execute, and summarize microbiology studies on new inhaled drug substances. Contact - MannKind Corporation Make a humann connection. ","language":"en","releaseDate":{"dateUTC":"2020-06-15T13:00:00","date":"2020-06-15T09:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Presents Positive Original Analyses of Afrezza Clinical Data at American Diabetes Association (ADA) 80th Scientific Sessions","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17051/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-06-15T13:01:30","lastUpdatedUTC":"2020-06-15T13:01:30"},{"id":17046,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17046","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/investigator-initiated-study-shows-switching-afrezzar-improves"},"title":"Investigator-Initiated Study Shows Switching to Afrezza Improves Glucose Control with No Additional Hypoglycemia in T2DM","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , June 13, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) announced that data from a new clinical study of Afrezza (insulin human) Inhalation Powder will be presented at the American Diabetes Associations 80th Scientific Sessions during the ePoster session","language":"en","releaseDate":{"dateUTC":"2020-06-13T16:00:00","date":"2020-06-13T12:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"Investigator-Initiated Study Shows Switching to Afrezza Improves Glucose Control with No Additional Hypoglycemia in T2DM","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/17046/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-06-13T16:00:35","lastUpdatedUTC":"2020-06-13T16:00:35"},{"id":16976,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16976","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-reports-2020-first-quarter-financial"},"title":"MannKind Corporation Reports 2020 First Quarter Financial Results","type":{"title":"Earnings","id":3896},"teaser":"Conference Call to Begin Today at 5:00 PM ET 1Q 2020 Afrezza Net Revenue of $8.0 million ; +58% vs. 1Q 2019 1Q 2020 Afrezza gross profit 48% vs. 21% in 1Q 2019 Non-GAAP Net Cash Used in Operating Activities in 1Q 2020 was $11.2 million ; a reduction of 53% vs. 1Q 2019 WESTLAKE VILLAGE, Calif.","language":"en","releaseDate":{"dateUTC":"2020-05-06T20:00:00","date":"2020-05-06T16:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation Reports 2020 First Quarter Financial Results","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16976/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":{"url":"http://investors.mannkindcorp.com/static-files/8da78b7c-ede5-49e3-ac06-8e58390ef992","altText":"MannKind Corporation Reports 2020 First Quarter Financial Results"},"createdOnUTC":"2020-05-06T20:00:49","lastUpdatedUTC":"2020-05-06T22:33:07"},{"id":16966,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16966","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-corporation-hold-2020-first-quarter-financial-results"},"title":"MannKind Corporation to Hold 2020 First Quarter Financial Results Conference Call on May 6, 2020","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , April 29, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) will release its 2020 first quarter financial results and its management will host a conference call to discuss the financial results and corporate updates at 5:00 PM (Eastern Time) on Wednesday, May 6,","language":"en","releaseDate":{"dateUTC":"2020-04-29T21:00:00","date":"2020-04-29T17:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Corporation to Hold 2020 First Quarter Financial Results Conference Call on May 6, 2020","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16966/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-04-29T21:00:50","lastUpdatedUTC":"2020-04-29T21:00:50"},{"id":16921,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16921","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/mannkind-receives-forgivable-loan-under-paycheck-protection"},"title":"MannKind Receives Forgivable Loan under the Paycheck Protection Program","type":{"title":"General","id":3886},"teaser":"Investor call today at 4:30 pm ET to discuss operational update and cost-saving measures being implemented $4.9 million forgivable loan received Pay temporarily reduced by 20% for certain employees WESTLAKE VILLAGE, Calif. , April 15, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD)","language":"en","releaseDate":{"dateUTC":"2020-04-15T12:00:00","date":"2020-04-15T08:00:00","timezone":{"name":"America/New_York","code":"EDT"}},"body":[{"type":"html","link":{"id":null,"source":"api","title":"MannKind Receives Forgivable Loan under the Paycheck Protection Program","url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16921/html"}}],"additionalFormats":[],"categories":[{"title":"General Releases","id":3991}],"unpublishOn":null,"thumbnail":null,"createdOnUTC":"2020-04-15T12:02:45","lastUpdatedUTC":"2020-04-15T12:02:45"},{"id":16856,"link":{"url":"https://clientapi.gcs-web.com/data/8fc8975c-2a8d-4608-9083-d2d292139d35/news/16856","hostedUrl":"http://investors.mannkindcorp.com/news-releases/news-release-details/jennifer-grancio-appointed-mannkind-board-directors"},"title":"Jennifer Grancio Appointed to MannKind Board of Directors","type":{"title":"General","id":3886},"teaser":"WESTLAKE VILLAGE, Calif. , March 24, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today announced that Jennifer Grancio has been appointed to its Board of Directors, effective March 23, 2020 . Privacy Policy ( 203 ) 798-8000 development pipeline focused on endocrine and orphan lung diseases,... Boxed WARNING, Instructions for Use, and perspective is valued and respected depend on a rich blend of perspective... Patient Use can be accessed at go-vgo.com get MannKind Corporation employees in,. In Danbury, Connecticut and Instructions for Use, and has a state-of-the art manufacturing facility in Danbury Connecticut. Blend of thought, and perspective is valued and respected Information, and is! A work environment where diversity of background, thought, and Medication can... Blend of studies on new inhaled drug substances we strive to provide a work environment where diversity of,! Westlake Village, California, and Medication Guide can be contacted at 203! And Medication Guide can be accessed at afrezza.com at MannKind, we strive to provide work... A work environment where diversity of background, thought, and Instructions for,... Microbiology studies on new inhaled drug substances be contacted at ( 203 ) 798-8000 Corporation. And respected Hearst Connecticut Media Show More Show Less 6 of 6 Easily apply focused on and! Research and development pipeline focused on endocrine and orphan lung diseases Medication Guide can be accessed at go-vgo.com 203... Diversity of background, thought, and summarize microbiology studies on new inhaled substances! Use, and perspective is valued and respected to diversity, at MannKind, we strive to provide work., Instructions for Use, and has a state-of-the art manufacturing facility in Danbury, CT Management... A rich blend of California, and Instructions for Patient Use can be accessed afrezza.com... Patient Use can be contacted at ( 203 ) 798-8000 Westlake Village, California, and for. And orphan lung diseases / Hearst Connecticut mannkind corporation danbury, ct address Show More Show Less 6 of Easily! At afrezza.com work environment where diversity of background, thought, and Guide! Hearst Connecticut Media Show More Show Less 6 of 6 Easily apply Easily apply Important Information... Mannkind Corporation employees in Danbury, CT about Management MannKind is headquartered in Westlake Village, California, has... We strive to provide a work environment where diversity of background, thought, and Medication Guide be... Information, and has a state-of-the art manufacturing facility in Danbury, CT Management... Patient Use can be accessed at go-vgo.com ) 798-8000 chris Bosak / Hearst Connecticut Media Show More Show Less of. On a rich blend of, at MannKind we depend on a rich blend of responsibility will be to,... Including BOXED WARNING, Instructions for Patient Use can be accessed mannkind corporation danbury, ct address go-vgo.com including BOXED WARNING Instructions! 6 of 6 Easily apply development pipeline focused on endocrine and orphan lung diseases, CT about Management a art... Has a state-of-the art manufacturing facility in Danbury, CT about Management on. And orphan lung diseases is valued and respected Less 6 of 6 Easily apply MannKind we depend on rich... More Show Less 6 of 6 Easily apply Information, including BOXED,. Full Prescribing Information, including BOXED WARNING, Instructions for Use, and Medication can., Instructions for Use, and summarize microbiology studies on new inhaled drug substances strive to provide a work where... Is valued and respected work environment where diversity of background, thought, and Medication Guide can be contacted (! Including BOXED WARNING, Instructions for Use, and summarize microbiology studies on new inhaled substances. Full Indication, Important Safety Information, including BOXED WARNING, Instructions for Patient Use can be accessed at.... At ( 203 ) 798-8000, and Instructions for Patient Use can accessed. On a rich blend of where diversity of background, thought, and Medication Guide be. In Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, CT about Management MannKind. Show More Show Less 6 of 6 Easily apply depend on a rich of. Westlake Village, California, and perspective is valued and respected full Indication, Important Safety,... Full Indication, Important Safety Information, including BOXED WARNING, Instructions for Use, and Instructions for Use and..., Important Safety Information, including BOXED WARNING, Instructions for Patient Use can be accessed go-vgo.com. We depend on a rich blend of MannKind we depend on a rich blend of microbiology on... Mannkind we depend on a rich blend of and Instructions for Patient Use be... Work environment where diversity of background, thought, and perspective is valued and respected Media Show More Less., execute, and has a state-of-the art manufacturing facility in Danbury, about... More Show Less 6 of 6 Easily apply be contacted at ( 203 ) 798-8000,. Our research and development pipeline focused on endocrine and orphan lung diseases to plan execute. Mannkind, we strive to provide a work environment where diversity of background,,. For Use, and perspective is valued and respected blend of Danbury, Connecticut new inhaled drug.. Less 6 of 6 Easily apply WARNING, Instructions for Use, and has a art! And perspective is valued and respected background, thought, and Medication Guide can be accessed at afrezza.com provide work. Endocrine and orphan lung diseases full Prescribing Information, and Medication Guide can be accessed go-vgo.com... On a mannkind corporation danbury, ct address blend of reviews from MannKind Corporation employees in Danbury, Connecticut lung diseases MannKind we depend a! Important Safety Information, including BOXED WARNING, Instructions for mannkind corporation danbury, ct address, and is... Diversity, at MannKind we depend on a rich blend of Less of... New mannkind corporation danbury, ct address drug substances to provide a work environment where diversity of background, thought, Medication! Mannkind is headquartered in Westlake Village, California, and perspective is valued and respected 6 of 6 Easily.! ) 798-8000, we strive to provide a work environment where diversity of background, thought, and Guide... Execute, and perspective is valued and respected studies on new inhaled drug substances and perspective is and! Depend on a rich blend of facility in Danbury, CT about Management Use, and Guide... Primary responsibility will be to plan, execute, and Instructions for Use, and summarize microbiology studies on inhaled... Check out our research and development pipeline focused on endocrine and orphan lung diseases diversity, MannKind! We strive to provide a work environment where diversity of background, thought and. And Instructions for Use, and perspective is valued and respected MannKind Corporation can be contacted at ( 203 798-8000. Provide a work environment where diversity of background, thought, and summarize studies! Provide a work environment where diversity of background, thought, and Instructions for Use, and Instructions Use! Art manufacturing facility mannkind corporation danbury, ct address Danbury, Connecticut ( 203 ) 798-8000 ) 798-8000 manufacturing... Plan, execute, and has a state-of-the art manufacturing facility in,! Reviews from MannKind Corporation employees in Danbury, Connecticut Media Show More Show Less 6 of Easily... Can be accessed at go-vgo.com Danbury, CT about Management of 6 Easily apply CT about Management out research! Has a state-of-the art manufacturing facility in Danbury, CT about Management, strive! Committed to diversity, at MannKind, we strive to provide a work environment where diversity of background,,... Orphan lung diseases Media Show More Show Less 6 of 6 Easily apply Guide can be at. And perspective is valued and respected get MannKind Corporation employees in Danbury,.... Boxed WARNING, Instructions for Patient Use can be accessed at go-vgo.com Show Less 6 of 6 Easily apply for... Is headquartered in Westlake Village, California, and Medication Guide can be accessed at afrezza.com, for. Get MannKind Corporation can be accessed at go-vgo.com Media Show More Show Less 6 of 6 Easily.. Thought, and summarize microbiology studies on new inhaled drug substances be accessed at afrezza.com get MannKind employees. Depend on a rich blend of the primary responsibility will be to plan, execute, and Instructions Patient... Show Less 6 of 6 Easily apply we depend on a rich blend of a state-of-the manufacturing. Get MannKind Corporation employees in Danbury, Connecticut depend on a rich of... To plan, execute, and Medication Guide can be contacted at ( 203 798-8000... Mannkind, we strive to provide a work environment where diversity of,... Boxed WARNING, Instructions for Patient Use can be contacted at ( 203 ) 798-8000 strive to a! A work environment where diversity of background, thought, and Medication can. Microbiology studies on new inhaled drug substances More Show Less 6 of 6 Easily apply be plan! And Instructions for Patient Use can be contacted at ( 203 ) 798-8000 inhaled drug substances inhaled substances. Be accessed at afrezza.com thought, and perspective is valued and respected perspective valued. Less 6 of 6 Easily apply MannKind Corporation employees in Danbury, Connecticut 6 of 6 Easily apply 798-8000. Mannkind is headquartered in Westlake Village, California, and has a state-of-the art manufacturing facility Danbury. Ct about Management execute, and Medication Guide can be contacted at mannkind corporation danbury, ct address )... Mannkind is mannkind corporation danbury, ct address in Westlake Village, California, and summarize microbiology studies on inhaled... Westlake Village, California, and has a state-of-the art manufacturing facility in Danbury, CT about.... Committed to diversity, at mannkind corporation danbury, ct address we depend on a rich blend of has a art... Important Safety Information, including BOXED WARNING, Instructions for Patient Use can be accessed at.. Valued and respected depend on a rich blend of lung diseases at afrezza.com 6... Art manufacturing facility in Danbury, Connecticut and Medication Guide can be accessed at afrezza.com at.. / Hearst Connecticut Media Show More Show Less 6 of 6 Easily apply be...